Ian Gilham is Chair of LifeArc Board of Trustees and Chair of the Nominations and Board Financial Approvals Committees. Ian is an experienced leader with an international track record in the research, development and commercialisation of diagnostic and pharmaceutical products. He has proven success as a leader in mergers and acquisitions and has strong fund manager, investor relations and advisor networks in the City of London and globally. Ian is currently non-executive chair of Genedrive plc, RevoNa Bio and Pelago BioScience. He previously held various global management roles at Celltech, Amersham International, Abbott Laboratories and GSK and was CEO of Axis-Shield plc, leading to its successful sale to Alere. Subsequently, he became Executive Chair at Horizon Discovery, leading the sale of the company to Perkin-Elmer.
Dr Ian Gilham
Latest news
-
First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases
Read more: First-of-a-kind plan announced to get more children access to cutting-edge, proven gene therapy treatments for rare diseases -
New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya
Read more: New £6.2m partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya -
LifeArc supports 8 new fellows through Crick Africa Network (CAN) partnership
Read more: LifeArc supports 8 new fellows through Crick Africa Network (CAN) partnership